Revelation Biosciences Inc (REVB) - Total Liabilities
Based on the latest financial reports, Revelation Biosciences Inc (REVB) has total liabilities worth $2.43 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Revelation Biosciences Inc (REVB) investment intensity to see how much of total assets are deployed in long-term investments.
Revelation Biosciences Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Revelation Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Revelation Biosciences Inc's balance sheet.
Revelation Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Revelation Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YouGov plc
LSE:YOU
|
UK | GBX377.90 Million |
|
Cash.Medien AG
HM:MF8
|
Germany | €861.26K |
|
Basin Energy Ltd
AU:BSN
|
Australia | AU$222.06K |
|
Techfast Holdings Bhd
KLSE:0084
|
Malaysia | RM5.07 Million |
|
Soligenix Inc.
NASDAQ:SNGX
|
USA | $3.70 Million |
|
GreenPower Motor Company Inc
NASDAQ:GP
|
USA | $40.31 Million |
|
Essentra PLC
LSE:ESNT
|
UK | GBX225.50 Million |
|
E-Home Household Service Holdings Ltd
NASDAQ:EJH
|
USA | $10.27 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Revelation Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Revelation Biosciences Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Revelation Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Revelation Biosciences Inc (2016–2025)
The table below shows the annual total liabilities of Revelation Biosciences Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.72 Million | +42.24% |
| 2024-12-31 | $1.91 Million | -65.61% |
| 2023-12-31 | $5.56 Million | +25.03% |
| 2022-12-31 | $4.45 Million | +107.83% |
| 2021-12-31 | $2.14 Million | -66.25% |
| 2020-12-31 | $6.34 Million | +24016.88% |
| 2019-12-31 | $26.31K | -100.00% |
| 2018-12-31 | $2.19 Billion | +14.64% |
| 2017-12-31 | $1.91 Billion | +10.72% |
| 2016-12-31 | $1.73 Billion | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregul… Read more